Cargando…
Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1
Antisense oligonucleotides (ASOs) have demonstrated variation of efficacy in patient populations. This has prompted our investigation into the contribution of genetic architecture to ASO pharmacokinetics (PK) and pharmacodynamics (PD). Genome wide association (GWA) and transcriptomic analysis in a h...
Autores principales: | Pirie, Elaine, Ray, Shayoni, Pan, Calvin, Fu, Wuxia, Powers, Andrew F., Polikoff, Danielle, Miller, Colton M., Kudrna, Katrina M., Harris, Edward N., Lusis, Aldons J., Crooke, Rosanne M., Lee, Richard G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224167/ https://www.ncbi.nlm.nih.gov/pubmed/30372444 http://dx.doi.org/10.1371/journal.pgen.1007732 |
Ejemplares similares
-
Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr(−/−) mice
por: Bell, Thomas A., et al.
Publicado: (2013) -
Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017) -
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015) -
Antisense oligonucleotides targeting angiotensinogen: insights from animal studies
por: Wu, Chia-Hua, et al.
Publicado: (2019) -
Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice
por: Bell, Thomas A., et al.
Publicado: (2021)